AD Combination Therapy Trial: Anti-Aβ + Anti-Tau

Experiment Proposal: Anti-Aβ + Anti-Tau Combination Therapy in Early AD

Hypothesis

Combined anti-amyloid ([lecanemab](/entities/lecanemab)/donanemab) and anti-[tau](/proteins/tau) (gosuranemab/tilavonemab) immunotherapy will demonstrate synergistic disease-modifying effects compared to monotherapy in early-stage Alzheimer's disease, with greater preservation of cognition and reduced neurodegeneration.

Key Distinction

This experiment tests whether dual targeting of Aβ and tau pathologies produces synergistic benefits beyond what either monotherapy can achieve alone. Current trials test each pathway independently — this addresses the critical gap of whether combination therapy is safe and effective.

Experimental Design

Phase 2 Randomized Controlled Trial

Population: Early AD (MCI due to AD or mild AD dementia), ages 60-85, amyloid PET positive, tau PET positive Sample Size: 450 participants (150 per arm) Duration: 24 months treatment, 12 months follow-off

Treatment Arms

Arm A (Monotherapy): Lecanemab monotherapy (10mg/kg q2w IV)

Arm B (Monotherapy): Anti-tau antibody monotherapy (gosuranemab or tilavonemab)

Arm C (Combination): Lecanemab + anti-tau antibody concurrent therapy

Study Protocol

Inclusion Criteria

• Clinical diagnosis of MCI due to AD or mild AD dementia
• MMSE score 20-30
• Amyloid PET Centiloid ≥ 50
• Tau PET (Braak I-III) positive
• MRI with no significant vascular burden (Fazekas < 2)
• Stable on cholinesterase inhibitor if on one

...

Experiment Proposal: Anti-Aβ + Anti-Tau Combination Therapy in Early AD

Hypothesis

Combined anti-amyloid ([lecanemab](/entities/lecanemab)/donanemab) and anti-[tau](/proteins/tau) (gosuranemab/tilavonemab) immunotherapy will demonstrate synergistic disease-modifying effects compared to monotherapy in early-stage Alzheimer's disease, with greater preservation of cognition and reduced neurodegeneration.

Key Distinction

This experiment tests whether dual targeting of Aβ and tau pathologies produces synergistic benefits beyond what either monotherapy can achieve alone. Current trials test each pathway independently — this addresses the critical gap of whether combination therapy is safe and effective.

Experimental Design

Phase 2 Randomized Controlled Trial

Population: Early AD (MCI due to AD or mild AD dementia), ages 60-85, amyloid PET positive, tau PET positive Sample Size: 450 participants (150 per arm) Duration: 24 months treatment, 12 months follow-off

Treatment Arms

Arm A (Monotherapy): Lecanemab monotherapy (10mg/kg q2w IV)

Arm B (Monotherapy): Anti-tau antibody monotherapy (gosuranemab or tilavonemab)

Arm C (Combination): Lecanemab + anti-tau antibody concurrent therapy

Study Protocol

Inclusion Criteria

• Clinical diagnosis of MCI due to AD or mild AD dementia
• MMSE score 20-30
• Amyloid PET Centiloid ≥ 50
• Tau PET (Braak I-III) positive
• MRI with no significant vascular burden (Fazekas < 2)
• Stable on cholinesterase inhibitor if on one

Exclusion Criteria

• Prior anti-Aβ or anti-tau immunotherapy
• Significant psychiatric disease
• Active malignancy
• Contraindications for MRI/PET

Endpoints

Primary Endpoints

Clinical: Change in CDR-SB at 24 months

Biomarker: Change in plasma [p-tau217](/biomarkers/p-tau-217) from baseline

Secondary Endpoints

Clinical: ADAS-Cog14, MMSE, ADCS-MCI-ADL

Biomarker: CSF [Aβ42](/proteins/amyloid-beta)/40, CSF total tau, CSF p-tau181, amyloid PET, tau PET

Safety: ARIA-E, ARIA-H, infusion reactions

Exploratory Endpoints

Brain volume (MRI)

Network connectivity (fMRI)

Cognitive reserve biomarkers (CSF neurogranin)

Microglial activation (PET PK11195)

Reagents and Costs

Direct Costs (Per Arm, 150 participants)

| Item | Cost (USD) |
|------|------------|
| Study drug (lecanemab) | $2,400,000 |
| Study drug (anti-tau) | $1,800,000 |
| MRI scans (baseline + 4) | $450,000 |
| PET scans (amyloid + tau) | $900,000 |
| Plasma biomarkers | $180,000 |
| CSF collection | $300,000 |
| Clinical assessments | $450,000 |
| Site management | $600,000 |
| Data management | $300,000 |
| Statistical analysis | $150,000 |
| Subtotal | $7,530,000 |

Total Trial Cost

• 3 arms × $7.53M = $22.59M
• Add 15% contingency = $25.98M
• Total: ~$26M

Timeline

| Phase | Duration | Activities |
|-------|----------|------------|
| Startup | 6 months | IRB, sites, supply chain |
| Recruitment | 12 months | Enrollment of 450 participants |
| Treatment | 24 months | Dosing and assessments |
| Follow-off | 12 months | Safety monitoring |
| Analysis | 6 months | Data lock to report |
| Total | 60 months (5 years) | — |

Suggested Investigators (Global Diversity)

Primary

• Dr. Reisa Sperling (Harvard, USA) — PI, amyloid expert
• Dr. Jeffrey Cummings (Cleveland Clinic, USA) — AD trials
• Dr. Philip Scheltens (VUmc, Netherlands) — European PI
• Dr. Takeshi Iwatsubo (University of Tokyo, Japan) — Asia-Pacific PI
• Dr. Ricardo Allegri (Fleni, Argentina) — Latin America PI

Key Sites (Targeting Geographic Diversity)

Massachusetts General Hospital (USA)

VU University Medical Center (Netherlands)

Tokyo Metropolitan Institute (Japan)

Fleni (Argentina)

Seoul National University (Korea)

Oxford University (UK)

Scoring (10 Dimensions)

| Dimension | Score (1-10) | Rationale |
|-----------|--------------|-----------|
| Scientific value | 9 | Tests synergistic dual-targeting hypothesis |
| Clinical relevance | 10 | Direct impact on treatment paradigm |
| Feasibility | 7 | Complex but doable at specialized centers |
| Discriminative power | 9 | Can distinguish monotherapy vs combo |
| Novelty | 10 | First large combo trial |
| Cost-efficiency | 6 | Expensive but comprehensive |
| Timeline | 5 | 5 years is lengthy but necessary |
| Safety monitoring | 7 | ARIA risk manageable |
| Regulatory path | 8 | Clear pathway with existing approvals |
| Global applicability | 9 | Multi-regional design |

Composite Score: 7.8 / 10

Expected Outcomes

If Combination Therapy Superior

• Significantly greater CDR-SB slowing vs either monotherapy
• Greater reduction in amyloid and tau PET
• May identify synergy biomarkers

If No Difference

• Suggests sequential rather than concurrent treatment may be better
• Guides future trial design

If Combination Worse

• Safety concerns with concurrent immunotherapy
• Suggests need for staggered approach

Risks and Mitigations

| Risk | Likelihood | Mitigation |
|------|------------|------------|
| ARIA (ARIA-E/H) | Medium | Strict inclusion, weekly monitoring |
| Drug-drug interactions | Low | PK sampling in subset |
| Recruitment challenges | Medium | Multi-continental sites |
| Dropout | Medium | Retention incentives |

See Also

• [Experiment Index](/experiments/experiment-index)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)

Overview

This page provides information about AD Combination Therapy Trial: Anti-Abeta + Anti-Tau.

References

[Unknown, Lecanemab CLARITY-AD Trial (2022) (2022)](https://doi.org/10.1056/NEJMoa2204143)

[Unknown, Donanemab TRAILBLAZER-ALZ 2 (2023) (2023)](https://doi.org/10.1056/NEJMoa2305030)

[Unknown, Gosuranemab TANGO Trial (2022) (2022)](https://doi.org/10.1002/alz.060722)

[Unknown, Anti-tau therapy mechanisms review (2023) (2023)](https://doi.org/10.1038/s41582-023-00792-4)

[Unknown, Amyloid-tau interaction biology (2024) (2024)](https://doi.org/10.1002/alz.14291)

[Unknown, Combination therapy in neurodegenerative disease (2023) (2023)](https://doi.org/10.1002/alz.12856)